市场调查报告书
商品编码
1541699
静脉注射(IV) 布洛芬市场报告(依产品剂量(100 毫克剂量、200 毫克剂量、400 毫克剂量、800 毫克剂量)、适应症(疼痛/发炎、发烧)、年龄层(儿科、成人)和地区2024-2032Intravenous (IV) Ibuprofen Market Report by Product Dose (100 Mg Dose, 200 Mg Dose, 400 Mg Dose, 800 Mg Dose), Indication (Pain/Inflammatory, Fever), Age Group (Pediatrics, Adults), and Region 2024-2032 |
IMARC Group年,全球静脉注射(IV)布洛芬市场规模达68亿美元。 。
布洛芬属于非类固醇类抗发炎药 (NSAID),用于治疗发炎、疼痛和发烧。它抑制合成前列腺素 (PG) 所需的环氧合酶 COZ-1 和 COX-2。静脉注射 (IV) 布洛芬可单独使用或与其他药物一起使用,以缓解轻度至重度不适。它被直接注射到静脉中,以阻止身体产生某些引起发炎的天然物质。它具有出色的安全性,有助于减少麻醉镇痛需求并降低疼痛程度。静脉注射布洛芬也有助于改善疼痛控制并减少骨科和腹部手术中阿片类药物的使用以及发烧。
全球范围内老年人口的稳定增长以及关节炎、心血管疾病 (CVD) 和癌症患病率的不断上升正在为市场创造积极的前景。与此一致的是,用于管理和治疗发炎性疾病、类风湿性疾病、轻度至中度疼痛、发烧、经痛和骨关节炎的产品的广泛采用有利于市场成长。此外,繁忙的工作日程和不健康的生活方式,以及随之而来的体力活动和适当营养的减少,导致慢性病的发病率上升,这是另一个促进生长的因素。除此之外,儿科治疗轻度发烧、牙痛、胃肠道疼痛和动脉导管的产品使用量不断增加,也推动了市场成长。此外,静脉注射布洛芬用于缓解肌肉或风湿疼痛、背痛、神经痛、扭伤、拉伤、运动伤害和肌肉骨骼疾病,这促进了市场成长。此外,骨科患者在膝关节或髋关节置换手术后对静脉注射布洛芬的需求不断增加,以减轻疼痛和吗啡的使用,这对市场成长产生了积极影响。其他因素,包括医疗基础设施的显着改善、个人健康意识的增强以及消费者支出能力的提高,预计将推动市场成长。
The global intravenous (IV) ibuprofen market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.79% during 2024-2032.
Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.
The steadily rising geriatric population and the increasing prevalence of arthritis, cardiovascular diseases (CVDs), and cancer across the globe are creating a positive outlook for the market. In line with this, the widespread product adoption to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis is favoring the market growth. Moreover, hectic working schedules and unhealthy lifestyles, along with a consequent decline in physical activity and proper nutrition, have led to a rise in the incidences of chronic diseases, which is acting as another growth-inducing factor. Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth. Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global intravenous (IV) ibuprofen market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product dose, indication and age group.
100 Mg Dose
200 Mg Dose
400 Mg Dose
800 Mg Dose
Pain/Inflammatory
Fever
Pediatrics
Adults
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.